Category Archives: Pharmacogenomics

InvestorPlace

With so much death and economic destruction wrought by the novel coronavirus, its hard to find the silver lining. But if there is one on Wall Street, its the rise of artificial intelligence stocks. Yes, there is the profitability angle from machine learning and other relevant technology facilitates. But this crisis has been a crash course in the sectors viability.Hopefully, we wont suffer a second wave like many European countries are experiencing because, you know, people can just get over themselves and wear a flipping mask in public. But even if we do succumb to a second round, eventually, this too shall pass. However, the return to some sense of normalcy will likely take time. Thus, we may depend on contactless platforms. Of course, this international emergency has provided an excellent arena for finetuning.As well, its becoming clear that the scale and acceleration of our globalized economy is more than human brains can handle. Yes, we are the ultimate innovative species (as far as I know). However, machines can now play a major role in alleviating most if not one day all of our menial tasks. That frees us up for greater and more meaningful innovations, which is the underlying ethos of artificial intelligence stocks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis isnt just techno-babble gibberish. For instance, the food supply chain was put under enormous stress during the peak of Covid-19. Well before the pandemic, many retailers partnered with AI programmers to develop enhanced forecasting and planning infrastructure. Now, this need has accelerated due to the baptism of fire. Therefore, these diverse artificial intelligence stocks could enjoy upside throughout this year and beyond.Apple (NASDAQ:AAPL)Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL)IBM (NYSE:IBM)Nvidia (NASDAQ:NVDA)Tencent (OTCMKTS:TCEHY)Match Group (NASDAQ:MTCH)Trade Desk (NASDAQ:TTD)The 7 Top Robinhood Stocks for OctoberFinally, not everything about AI has to be so serious. Since were conducting our business and personal affairs increasingly online, almost anything that we can think of, including love and dating, can benefit from the integration of man and machine. Since this dynamic is well under way, here are the seven artificial intelligence stocks from which you can profit.Apple (AAPL)Source: View Apart / Shutterstock.comAs the manufacturer of the now-iconic iPhone, Apple is more well known as a consumer electronics behemoth rather than an investment into artificial intelligence stocks. Certainly, the company can bank simply on the power of its globally recognized brand. However, what makes AAPL stock special is that management refuses to be satisfied with its prior accomplishments.As evidence, consider Apples foray into electric vehicles. At one point, rumors circulated that hundreds of people were developing a car, one that could possibly compete with Tesla (NASDAQ:TSLA). Nowadays, it appears that the consumer tech firm is focusing on developing software for self-driving cars. If thats the case, such a course would require significant innovations in AI, particularly machine learning.Theoretically, Apple has a lot of practice in this arena thanks to its wealth of consumer data. In addition, the company has forged consumer friendly applications, such as palm rejection technology. This nifty development allows the iPad to recognize the difference between a deliberate input with the Apple Pencil versus accidental contact with a part of the hand.Undoubtedly, most investors will buy AAPL stock for its ever-popular smart devices. However, those who are interested in artificial intelligence stocks should also give it serious consideration.Alphabet (GOOG, GOOGL)Source: BigTunaOnline / Shutterstock.comWhenever anyone talks about artificial intelligence stocks, Alphabet is one of the top names thats mentioned and for good reason. Essentially, Alphabets Google owns the internet. As of July 2020, Google dominated desktop search engines with an 87% global market share. With figures like that, youre bound to have a wealth of consumer data that other organizations can only dream about.And with search dominance comes its web advertisement-driven revenue channels. Corporations spend billions buying up Google ads because thats where the people are. In turn, Alphabet has gotten quite adept at utilizing its AI infrastructure to fine-tune what consumers want and just as importantly, when they want it. Additionally, thanks to its YouTube platform, Alphabet has years of valuable experience understanding and predicting consumer behavior.Therefore, while GOOGL stock is often the target of social and political criticism, I dont see the internet giant going anywhere but up over a long-term horizon.7 Internet of Things Stocks for Investing in InnovationPlus, what really makes Alphabet stand out is its penchant for relevant acquisitions. For example, its DeepMind subsidiary specializes in traffic prediction algorithms. Thats not just important for everyday convenience but also as a framework for smart city infrastructures. Therefore, if you want more AI in your portfolio, go get some GOOGL stock.IBM (IBM)Source: JHVEPhoto / Shutterstock.comAlthough artificial intelligence stocks represent one of the hottest segments on Wall Street, individual names tend to be well-known entities. As such, theyre not exactly what you would call undervalued as they typically have already garnered much investor sentiment.Well, IBM doesnt have that problem. As a legacy tech giant, Big Blue has struggled over the years to shed its image of yesteryear innovations. Instead, management has pivoted to many relevant markets, including cloud computing and cybersecurity. However, IBM stock is frustrating, even in this year where its down 10% while other tech firms are up big.Nevertheless, if you want to go against the grain with your artificial intelligence stocks, IBM offers the patient investor potentially significant upside. As you know, with its AI platform Watson, Big Blue has been helping multiple enterprises and industries maximize their efficiency. One particular area that Im intrigued in is healthcare.With the novel coronavirus having disrupted this sector, theres never been a more critical time for improved efficiencies. Here, IBM could make a conspicuously positive impact, reducing administrative friction so that medical professionals can spend less time on paperwork and more time helping patients. Having learned tough lessons from the new normal, the pandemic could help IBM stock regain its footing.Nvidia (NVDA)Source: Hairem / Shutterstock.comWhen you hear the brand Nvidia, most likely what comes to mind first is video games. And thats not a bad thing, believe me. Before the pandemic, video games, especially the rise of eSports, helped drive the bullish case for NVDA stock. During the lockdowns and the new normal, this entertainment platform helped while away the hours when other options were off the table.Despite its dominance in gaming, Nvidia would like to let you know that its one of the leaders in artificial intelligence stocks as well. The companys partnership with Walmart (NYSE:WMT) illustrates this relationship perfectly. As a big-box retailer, Walmart must make critical decisions all the time about their inventory: how much to buy, when to ship them out and to which stores, among countless other concerns.Fortunately, Walmart has advanced data analytics software that references back decades of data for hundreds of millions of products. But all that data processing requires sophisticated hardware otherwise, youre not going anywhere. Thats where Nvidia comes in with its graphics processors. Sure, theyre best known for their gaming applications, but they can do so much more.The 7 Best Semiconductor Stocks to Buy TodayNot surprisingly, NVDA stock has significant links to other burgeoning industries, such as self-driving technologies and the blockchain. Therefore, youll want to keep this on your short list of artificial intelligence stocks to buy.Tencent (TCEHY)Source: StreetVJ / Shutterstock.comTaking aside the politics, if you want to broaden your portfolio of artificial intelligence stocks, you should look at China. Companies like Tencent really are in an enviable position. For one, Tencents home market has blossomed into a technological powerhouse. Second, Chinas massive population means ample room for growth, increased connectivity and the biggest data goldmine.Further, Tencent has wide-reaching ambitions regarding its AI initiatives. As an internet content and social media network provider, the company is finetuning personalized advertisements and suggestions for its millions of users. In addition, Tencent is pursuing more serious endeavors, such as medical AI applications. Here, the idea is to use technology to help physicians detect and prevent the spread of disease.With the coronavirus having originated from China as President Trump reminds us every day this application seems very relevant for TCEHY stock.Of course, nothing can be divorced from politics these days and so it is with Tencent. As the owner of WeChat, the messaging/payments app has come under fire from the Trump administration. And that might mean TCEHY stock is on shaky ground, at least until we figure out who will run our nation on Nov. 3. Still, the opportunity for upside is tantalizing because of the aforementioned attributes of the home market.Match Group (MTCH)Source: ShutterstockInvariably, analyses of artificial intelligence stocks typically involve high-scale solutions. Over this list, weve covered the impact that AI can have on our purchasing decisions, interactions with machines, forecasting inventory demand and improving health outcomes. But AI doesnt have to be so serious. Instead, it can help with that age-old longing for love.Thats right, for those of who want to give Cupid an assist, online dating apps, such as those under the Match Group umbrella, may help accelerate your search for a soulmate. But what if Cupid needs help too? Increasingly, the mythical god has turned to artificial intelligence to help provide appropriate matchups.In a way, this is the probably the most ingenious use of AI. By now, many of these dating sites and apps have collected an enormous amount of behavioral data. Thats also due to the stigma of online dating fading away. Plus, with the novel coronavirus disrupting offline dating, Match is one of the viable places to go. That right there is a great reason to consider MTCH stock.10 ESG Stocks to Buy for a Brighter FutureBetter yet, Match is wising up to the power of AI to promote a safe dating environment. The company invested in Noonlight to provide safety features such as location tracking in case a meetup goes awry. Thats smart thinking, which should separate MTCH stock from other social networking investments.Trade Desk (TTD)Source: BrightSpace / Shutterstock.comWell before the pandemic, the cord-cutting phenomenon was placing increased pressure on traditional cable TV providers. With the advent of connected TV and streaming services, these innovations sparked never-before-seen capabilities, such as on-demand viewing. Instead of people revolving their lives around content scheduling (as in linear TV), the new generation of entertainment adapted to the individual.Following the coronavirus impact, the pressure to cut the cord intensified for many households. This was especially true during the early days of the crisis, when new content offerings were thin but the bills kept piling up. But pandemic or not, streaming and connected TV is here to stay. And that makes Trade Desk a relevant idea among artificial intelligence stocks.Primarily, the company utilizes AI algorithms to maximize advertisers return for their connected TV dollars. Thats much easier now because Trade Desk has access to a wealth of viewership data. As a result, its able to pinpoint which advertising strategies will work best, bolstering the narrative for TTD stock.Further, with live sports returning, Trade Desk may have an opportunity to evangelize its services. Because of the added cord-cutting pressures, the live sports streaming audience has probably increased significantly. That plays into the hands of TTD stock, where the underlying company can help advertisers plan for the possibility of games that go into overtime, which will likely feature a substantial uptick in engaged viewers.On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.More From InvestorPlaceWhy Everyone Is Investing in 5G All WRONGAmericas #1 Stock Picker Reveals His Next 1,000% WinnerRevolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 CompanyCould Tiny Super Battery Kill Big Tech?The post 7 Artificial Intelligence Stocks to Buy for October appeared first on InvestorPlace.

Continued here:
Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas - Yahoo Finance

The "Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Global Precision Medicine Market to Reach $278.61 Billion by 2030

Precision medicine refers to the medicine developed as per an individual's genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.

In the precision medicine market, the application of molecular biology is to study the cause of a patient's disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems.

This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Key Topics Covered:

1 Product Definition

2 Research Scope

3 Research Methodology

4 Global Precision Medicine Market Overview

4.1 Market Definition

4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine

4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy

4.4 Initiatives and Programs

4.5 Precision Medicine: Enabling Technologies and Applications

4.5.1 Innovators

4.5.1.1 3D DNA Printing

4.5.1.1.1 Introduction

4.5.1.1.2 Role of 3D DNA Printing

4.5.1.2 RNA-Seq

4.5.1.2.1 Introduction

4.5.1.2.2 Role of RNA-Seq in Precision Medicine

4.5.1.2.3 Key Players

4.5.1.3 4D Molecular Imaging

4.5.1.3.1 Introduction

4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine

4.5.1.3.3 Key Players

4.5.2 Early Adopters

4.5.2.1 CRISPR

4.5.2.1.1 Introduction

4.5.2.1.2 Role of CRISPR in Precision Medicine

4.5.2.1.3 Key Players

4.5.2.2 Blockchain

4.5.2.3 Imaging Informatics

4.5.3 Early Majority

4.5.3.1 Artificial Intelligence (AI)

4.5.3.2 Circulating Free DNA (cfDNA)

4.5.3.3 Big Data

4.5.3.4 Next-Generation Sequencing (NGS)

4.5.3.5 Health Informatics

4.5.3.6 Bioinformatics

4.5.4 Late Majority

4.5.4.1 Polymerase Chain Reactions (PCR)

4.5.4.2 Microarray

4.6 COVID-19 Impact on the Global Precision Medicine Market

5 Market Dynamics

5.1 Overview

5.2 Market Drivers

5.2.1 Advancement of Sequencing Technologies

5.2.2 Rising Prevalence of Chronic Diseases

5.2.3 Growing Demand for Preventive Care

5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention

5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test

5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe

5.3 Market Restraints

5.3.1 Unified Framework for Data Integration

5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction

5.3.3 Lack of Robust Reimbursement Landscape

5.3.4 Regulatory Hurdles

5.4 Market Opportunities

5.4.1 Targeted Gene Therapy

5.4.2 Expansion into the Emerging Markets

5.4.3 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry

6 Industry Insights

6.1 Patent Analysis

6.2 Legal Requirements and Regulations

6.3 Pipeline Analysis

6.4 Legal Requirements and Framework by the FDA

6.5 Legal Requirements and Framework by the EMA

6.6 Legal Requirements and Framework by the MHLW

7 Competitive Landscape

7.1 Synergistic Activities

7.1.1 Product launches, Enhancements, and Upgradation

7.1.2 Product Approvals

7.1.3 Mergers and Acquisitions

7.1.4 Business Expansion

7.2 Market Share Analysis

7.2.1 Market Share Analysis by Applied Sciences, 2019

7.2.2 Market Share Analysis by Precision Diagnostics, 2019

7.2.3 Market Share Analysis by Precision Therapeutics, 2019

7.2.4 Market Share Analysis by Digital Health and IT, 2019

8 Global Precision Medicine Market (by Ecosystem)

8.1 Overview

8.2 Applied Sciences

8.2.1 Genomics

8.2.2 Global Precision Medicine Genomics Market (by Technology)

8.2.2.1 Polymerase Chain Reaction (PCR)

8.2.2.2 Next-Generation Sequencing (NGS)

8.2.2.3 Genome Editing

8.2.2.4 Other Technologies

8.2.3 Pharmacogenomics

8.2.4 Other Applied Sciences

8.3 Precision Diagnostics

8.3.1 Molecular Diagnostics (MDx)

8.3.2 Global Precision Medicine Molecular Diagnostics Market (by Type)

8.3.2.1 Non-Invasive Prenatal Testing (NIPT)

8.3.2.2 Companion Diagnostics

8.3.2.3 Liquid Biopsy

8.3.2.4 Other Molecular Diagnostics

Visit link:
Global Precision Medicine Market 2020-2030: Focus on Ecosystem, Technology, Application, and Competitive Landscape - ResearchAndMarkets.com - Benzinga

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market was valued at USD _ million/billion.

This research report based on Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2795996&source=atm

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Overview:

The Research projects that the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market:

segment by Type, the product can be split intoPCRIn-situ HybridizationImmunohistochemistrySequencingOthers

Market segment by Application, split intoOncologyNeurological DisordersCardiovascular DiseaseImmunological DisordersOthers

Based on regional and country-level analysis, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyQiagen NVGE HealthcareAgilent TechnologiesF Hoffman La RocheFoundation MedicineThermo Fisher Scientific Inc.Leica Biosystems Nussloch GmBHPfizer

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2795996&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2795996&licType=S&source=atm

The Questions Answered by Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report:

And Many More.

Read more here:
Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market and Forecast Analyzed in a New Research Report - The Daily Chronicle

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced a series of secure Application Programming Interfaces (APIs) that will offer provider and revenue cycle organizations connectivity to payers via the NaviNet Open Platform. This update enables faster information retrieval and easier payer access through a secure real-time, HIPAA-compliant gateway to payers. The workflows include Eligibility & Benefits, Claim Status Inquiry, Authorizations, and Referrals. NaviNet also offers APIs for payers to access the secure and flexible NaviNet Open Document Exchange platform.

The NaviNet Open Platform APIs provide benefits to stakeholders across the healthcare industry.

NantHealth is delighted to bring this additional functionality to our network of health plans and providers, leading to enhanced interoperability with automation, security, ease of use and scalability, said Chris House, Senior Vice President, Product Engineering at NantHealth. NaviNet has been a leader in payer-provider engagement for 20 years, creating value through innovation and enabling healthcare to successfully operate more efficiently, resulting in better care for patients and members.

About NantHealth, Inc.

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

Read the original post:
NantHealth Enhances Interoperability of the NaviNet Open Platform With Expanded API Capabilities - Business Wire

As the second wave of the coronavirus hits, Well Health Technologies(TSX:WELL) stock is seeing rapid growth. Technology has always been underappreciated and underutilized in primary care healthcare. But today, the coronavirus has brought its merits to light like never before. We now know two things for sure.

Firstly, today in this pandemic, we need technology in primary healthcare like never before. It is allowing us to access our doctors while maintaining distancing. Secondly, the benefits of technology in primary healthcare are multi-faceted. Technology will continue to transform and improve healthcare for the long haul.

Here are the reasons why WELL stockis a stock to buy.

Well Healths stock price has shot up in 2020. This is no surprise, as demand for telemedicine has skyrocketed in the pandemic. Well Healths revenue in the first six months of 2020 increased 40%. In 2019, Well Healths revenue increased 211%.

With a $938 million market capitalization and a rapidly growing healthcare asset base, Well Health continues to transform the primary healthcare industry. The company continues to acquire clinical and digital healthcare assets.

As the second wave hits, Well Healths clinics and services will be even more in demand. And the benefits of telemedicine will become more and more obvious. With this, Well Health stock will continue its rise.

Well Health has a fast-growing digital portfolio of healthcare assets. It has 2,000 clinics, over 10,000 supported general practitioners, and over 15 million registered patients. The companys clinic portfolio is also becoming more and more sizable. It has 19 wholly-owned clinics and approximately 180 doctors at these clinics.

The primary healthcare system is one of the last big industries that has yet to digitize. According to Well Health reports, the Canadian primary care industry is a $250 billion industry. Physician spending accounts for approximately 15.4%. The industry is plagued by underinvestment, fragmentation and a lack of technology.

Well Health aims to change this. The benefits are big and they are clear. Digital tools can increase operational efficiency. They can improve patient care. They can allow physicians to focus more on what matters.

Virtual care ensures easy access to doctors. This has been key in the coronavirus pandemic. It will be even more key as the second wave hits. Waiting room automation allows for shorter wait times for patients. These are examples of what technology can do. But there are also more significant advantages.

Precision medicine proposes customizing healthcare decisions, treatments, practices, and products to suit individual patient needs. It basically means identifying best approaches tailored for a specific patient. Genetic, environmental, and lifestyle factors all play a role in determining a patients treatment. We can easily see how a digital database of information on each patient is key for this purpose.

In the future, a digital database with patients DNA can take all this a step further. Pharmacogenomics is the study of how genes affect a persons response to particular drugs. A database that has genetic data, biological samples, and other health information will step up healthcare into a new age.

Well Health stock has so much going for it. It has a significant runway of growth ahead as it participates in the digitization of the healthcare system. Patient care is improving and primary care offices are becoming more efficient. WELL stock trades at just over $6.50 at the time of writing. It has risen 130% in the last three months. Expect more big increases in the short, medium, and long term.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

Visit link:
Why Well Health (TSX:WELL) Is the Stock to Buy as the 2nd COVID-19 Wave Hits - The Motley Fool Canada

Market Study Report, LLC, has added a detailed study on the Veterinary Therapeutics market which provides a brief summary of the growth trends influencing the market. The report also includes significant insights pertaining to the profitability graph, market share, regional proliferation and SWOT analysis of this business vertical. The report further illustrates the status of key players in the competitive setting of the Veterinary Therapeutics market, while expanding on their corporate strategies and product offerings.

The latest research report on the Veterinary Therapeutics market assesses the major factors influencing industry growth with respect to the competitive dynamics and geographical reach. It also ensembles the challenges prevalent in this industry vertical and identifies opportunities that will further aid business expansion. Further, the report revisits all areas of the business to cover the impact of COVID-19 pandemic so as to assist stakeholders in devising new strategies and reinforcing their position in the market.

Request a sample Report of Veterinary Therapeutics Market at:https://www.marketstudyreport.com/request-a-sample/2908669?utm_source=msf&utm_medium=RV

Key pointers from COVID-19 impact analysis:

Important inclusions in the Veterinary Therapeutics market report:

Ask for Discount on Veterinary Therapeutics Market Report at:https://www.marketstudyreport.com/check-for-discount/2908669?utm_source=msf&utm_medium=RV

Regional scope:

TOC of Veterinary Therapeutics Market Report Includes:

The Report Answers the key Questions

For More Details On this Report: https://www.marketstudyreport.com/reports/global-veterinary-therapeutics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

1. Global HIV Therapeutics Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-hiv-therapeutics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Pharmacogenomics (PGX) Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-pharmacogenomics-pgx-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more:
Veterinary Therapeutics Market 2020 Analysis & Forecast to 2026 by Key Players, - News.MarketSizeForecasters.com